Northern RNA and Providence Therapeutics announce agreement for GMP manufacturing
The value of the agreement signed between Northern RNA and Providence is in excess of $15 million dollars.
Research & Development
CALGARY — Northern RNA Inc. and Providence Therapeutics announced a multi-year agreement for Northern RNA to provide Plasmid DNA, mRNA Cap Analogs and Good Manufacturing Practices (GMP) certified manufacturing to support Providence’s COVID-19 messenger RNA (mRNA) vaccine development and manufacturing requirements. The value of the agreement signed between Northern RNA and Providence is in excess of $15 million dollars and represents a continued joint commitment to bring mRNA-based vaccines to global markets.
“Northern RNA will provide leading-edge manufacturing of two key building blocks for the COVID-19 vaccine, including Cap Analogs and Plasmid DNA, essential raw materials needed to produce messenger RNA. We are very pleased to be able to support Providence Therapeutics with our proven manufacturing capabilities,” said Brad Stevens, President and CEO, Northern RNA.
Covid-19 is a global challenge that has impacted us all. Providence Therapeutics provides vaccine solutions to help now, and in the future.
“We hold deep expertise in the science of mRNA and that experience has motivated us to work across the globe to supply a safe and effective Covid-19 vaccine with a focus on under-served markets,” said Brad Sorensen, CEO of Providence Therapeutics.
Both Northern RNA and Providence Therapeutics appreciate the opportunity to bring vaccine solutions to global markets.